NINTEDANIB: 26,243 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
26,243
Total FAERS Reports
5,822 (22.2%)
Deaths Reported
9,433
Hospitalizations
26,243
As Primary/Secondary Suspect
854
Life-Threatening
490
Disabilities
None
Status
FDA Application: 212609 ·
First Report: 1991 · Latest Report: 20250925
What Are the Most Common NINTEDANIB Side Effects?
#1 Most Reported
Diarrhoea
9,103 reports (34.7%)
#2 Most Reported
Nausea
4,198 reports (16.0%)
#3 Most Reported
Dyspnoea
3,080 reports (11.7%)
All NINTEDANIB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 9,103 | 34.7% | 1,063 | 3,967 |
| Nausea | 4,198 | 16.0% | 349 | 1,832 |
| Dyspnoea | 3,080 | 11.7% | 500 | 1,692 |
| Decreased appetite | 2,832 | 10.8% | 348 | 1,390 |
| Death | 2,790 | 10.6% | 2,783 | 545 |
| Weight decreased | 2,628 | 10.0% | 309 | 1,278 |
| Vomiting | 2,524 | 9.6% | 238 | 1,183 |
| Fatigue | 2,511 | 9.6% | 261 | 1,094 |
| Cough | 2,193 | 8.4% | 220 | 1,016 |
| Idiopathic pulmonary fibrosis | 1,905 | 7.3% | 960 | 909 |
| Constipation | 1,756 | 6.7% | 144 | 803 |
| Abdominal pain upper | 1,664 | 6.3% | 103 | 751 |
| Asthenia | 1,487 | 5.7% | 178 | 750 |
| Headache | 1,461 | 5.6% | 66 | 577 |
| Abdominal discomfort | 1,418 | 5.4% | 76 | 635 |
| Pneumonia | 1,260 | 4.8% | 431 | 1,020 |
| Dizziness | 1,145 | 4.4% | 73 | 529 |
| Productive cough | 1,027 | 3.9% | 120 | 561 |
| Malaise | 929 | 3.5% | 98 | 429 |
| Abdominal pain | 905 | 3.5% | 100 | 446 |
Who Reports NINTEDANIB Side Effects? Age & Gender Data
Gender: 41.8% female, 58.2% male. Average age: 70.7 years. Most reports from: US. View detailed demographics →
Is NINTEDANIB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2004 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 5 | 0 | 4 |
| 2012 | 5 | 1 | 4 |
| 2013 | 19 | 4 | 11 |
| 2014 | 184 | 38 | 73 |
| 2015 | 1,222 | 214 | 558 |
| 2016 | 1,451 | 411 | 815 |
| 2017 | 1,577 | 361 | 767 |
| 2018 | 1,497 | 403 | 582 |
| 2019 | 1,575 | 384 | 709 |
| 2020 | 1,790 | 385 | 701 |
| 2021 | 1,931 | 400 | 793 |
| 2022 | 1,850 | 377 | 776 |
| 2023 | 1,600 | 363 | 607 |
| 2024 | 1,494 | 380 | 584 |
| 2025 | 622 | 132 | 248 |
What Is NINTEDANIB Used For?
| Indication | Reports |
|---|---|
| Idiopathic pulmonary fibrosis | 13,678 |
| Product used for unknown indication | 6,075 |
| Interstitial lung disease | 2,999 |
| Pulmonary fibrosis | 1,539 |
| Lung adenocarcinoma | 793 |
| Non-small cell lung cancer | 580 |
| Systemic sclerosis pulmonary | 214 |
| Adenocarcinoma | 206 |
| Systemic scleroderma | 204 |
| Lung neoplasm malignant | 127 |
NINTEDANIB vs Alternatives: Which Is Safer?
NINTEDANIB vs NINTEDANIB ESYLATE
NINTEDANIB vs NIRAPARIB
NINTEDANIB vs NIRMATRELVIR\RITONAVIR
NINTEDANIB vs NIROGACESTAT
NINTEDANIB vs NIROGACESTAT HYDROBROMIDE
NINTEDANIB vs NIRSEVIMAB
NINTEDANIB vs NIRSEVIMAB-ALIP
NINTEDANIB vs NITAZOXANIDE
NINTEDANIB vs NITISINONE
NINTEDANIB vs NITRAZEPAM
Official FDA Label for NINTEDANIB
Official prescribing information from the FDA-approved drug label.